Dopamine-sensitive adenylyl cyclases in neuronal development: Physiopathological and pharmacological implications

Drug Discovery Today

Volumn 16, Issue 11-12, 2011, Pages 520-529

  Pavan, Barbara ^a   Paganetto, Guglielmo ^a   Dalpiaz, Alessandro ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 1; ADENYLATE CYCLASE 3; ADENYLATE CYCLASE 5; ADENYLATE CYCLASE 6; DOPAMINE; LEVODOPA; UNCLASSIFIED DRUG;

DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA;

ADENYLATE CYCLASE; ANIMALS; CELL DIFFERENTIATION; DOPAMINE; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES; NEUROGENESIS; NEURONS; SMALL MOLECULE LIBRARIES;

EID: 79958232982     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.03.010     Document Type: Review

References (97)

1. D. Van der Kooy, and S. Weiss Why stem cells? Science 287 2010 1439 1441
2. G.A. Elder Research update: neurogenesis in adult brain and neuropsychiatric disorders Mt. Sinai J. Med. 73 2006 931 940 (Pubitemid 46040390)
3. M. Tio Roles of db-cAMP. IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells PLoS ONE 24 2010 e9398
4. J.C. Borba Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development Brain Res. Dev. Brain Res. 156 2005 193 201
5. G. Kim Activation of protein kinase A induces neuronal differentiation of HiB5 hippocampal progenitor cells Brain Res. Mol. Brain Res. 109 2002 134 145 (Pubitemid 36078379)
6. W. Deng In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP Biochem. Biophys. Res. Commun. 282 2001 148 152 (Pubitemid 32924357)
7. C.A. Johnston Differentiation-induced alterations in cyclic AMP signaling in the Cath.a differentiated (CAD) neuronal cell line J. Neurochem. 88 2004 1497 1508 (Pubitemid 38366926)
8. B. Pavan Adenylyl cyclases as innovative therapeutics goals Drug Discov. Today 14 2009 982 991
9. Y. Chern Regulation of adenylyl cyclase in the central nervous system Cell Signal. 12 2000 195 204 (Pubitemid 30214223)
10. M.J. Howard Mechanisms and perspectives on differentiation of autonomic neurons Dev. Biol. 277 2005 271 286 (Pubitemid 40022951)
11. Y. Cai Gene expression profiling and analysis of signaling pathways involved in priming and differentiation of human neural stem cells Neuroscience 138 2006 133 148 (Pubitemid 43222076)
12. R. Donato Differential development of neuronal physiological responsiveness in two human neural stem cell lines BMC Neurosci. 8 2007 36
13. L. Lipskaia Different expression of adenylyl cyclase isoforms after retinoic acid induction of P19 teratocarcinoma cells FEBS Lett. 415 1997 275 280 (Pubitemid 27451948)
14. S.A. Morris, and J.P. Bilezikian Modifications of the adenylate cyclase complex during differentiation of cultured myoblasts J. Cell. Physiol. 127 1986 28 38 (Pubitemid 16113481)
15. J.J. Young 'Soluble' adenylyl cyclase-generated cyclic adenosine monophosphate promotes fast migration in PC12 cells J. Neurosci. Res. 86 2008 118 124
16. S. Bernascone Novel adenosine and cAMP signalling pathways in migrating glial cells Cell Calcium 48 2010 83 90
17. J.B. Pasuit Multi-modal regulation of endogenous D1 dopamine receptor expression and function in the CAD catecholaminergic cell line J. Neurochem. 89 2004 1508 1519 (Pubitemid 38802672)
18. E. Hermanson Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells Exp. Cell Res. 288 2003 324 334 (Pubitemid 36959948)
19. P.S. Goldman-Rakic D1 receptors in prefrontal cells and circuits Brain Res. Rev. 31 2000 295 301
20. N. Ben-Jonathan, and R. Hnasko Dopamine as a prolactin (PRL) inhibitor Endocr. Rev. 22 2001 724 763 (Pubitemid 34214293)
21. J.-L. Guillou Inhibition by calcium of mammalian adenylyl cyclases J. Biol. Chem. 274 1999 35539 35545 (Pubitemid 129512849)
22. D.M.F. Cooper Regulation and organization of adenylyl cyclases and cAMP Biochem. J. 375 2003 517 529 (Pubitemid 37433500)
23. M. Scarselli D2/D3 dopamine receptor heterodimers exhibit unique functional properties J. Biol. Chem. 276 2001 30308 30314
24. S.W. Robinson, and M.G. Caron Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor Mol. Pharmacol. 52 1997 508 514 (Pubitemid 27412977)
25. N. Mons, and D.M.F. Cooper Selective expression of one Ca2+-inhibitable adenylyl cyclase in dopaminergically innervated rat brain regions Mol. Brain Res. 22 1994 236 244
26. C.E. Glatt, and S.H. Snyder Cloning and expression of an adenylyl cyclase localized to the corpus striatum Nature 361 1993 536 538 (Pubitemid 23055614)
27. P. de Gortari, and G. Mengod Dopamine D1.D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells Brain Res. 1310 2010 37 45
28. I. Matsuoka Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain J. Neurochem. 68 1997 498 506 (Pubitemid 27044708)
29. I. Espinasse Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity J. Mol. Cell. Cardiol. 27 1995 1789 1795
30. R. Reddy Voltage-sensitive adenylyl cyclase activity in cultured neurons. A calcium-independent phenomenon J. Biol. Chem. 270 1995 14340 14346
31. T. Wang, and M.J. Brown Differential expression of adenylyl cyclase subtypes in human cardiovascular system Mol. Cell. Endocrinol. 223 2004 55 62 (Pubitemid 38992910)
32. F.A. Antoni Cellular localisation of adenylyl cyclase: a post-genome perspective Neurochem. Res. 31 2006 287 295
33. C.L. Hu Adenylyl cyclase type 5 protein expression during cardiac development and stress Am. J. Physiol. Heart Circ. Physiol. 297 2009 H1776 H1782
34. J.A. Col Adenylyl cyclase-dependent axonal targeting in the olfactory system Development 134 2007 2481 2489 (Pubitemid 47074142)
35. C. Perry Olfactory neural cells: an untapped diagnostic and therapeutic resource. The 2000 Ogura Lecture Laryngoscope 112 2002 603 607 (Pubitemid 34285922)
36. L.N. Borodinsky Activity-dependent homeostatic specification of transmitter expression in embryonic neurons Nature 429 2004 523 530 (Pubitemid 38737651)
37. 2+ fluctuations J. Neurobiol. 37 1998 110 130 (Pubitemid 28453389)
38. J.M. Fearnley, and A.J. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 1991 2283 2301
39. R.A. Fricker-Gates, and M.A. Gates Stem cell-derived dopamine neurons for brain repair in Parkinson's disease Regen. Med. 5 2010 267 278
40. F.J. Vingerhoets Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions Ann. Neurol. 36 1994 765 770 (Pubitemid 24979416)
41. N. Wood Genes and Parkinsonism J. Neurol. Neurosurg. Psychiatry 62 1997 305 309 (Pubitemid 27199099)
42. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458 (Pubitemid 36041148)
43. C. Rangel-Barajas l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata Neurobiol. Dis. 41 2011 51 61
44. A. Pinna Priming of 6-hydroxydopamine-lesioned rats with l-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue Eur. J. Pharmacol. 331 1997 23 26 (Pubitemid 27312407)
45. J. Tong Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Ann. Neurol. 55 2004 125 129 (Pubitemid 38067371)
46. G.F. Wooten Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease Parkinsonism Relat. Disord. 8 2001 79 83 (Pubitemid 32728019)
47. S. Nikolaus In vivo imaging of synaptic function in the central nervous system. I. Movement disorders and dementia Behav. Brain Res. 204 2009 1 31
48. T. Iwamoto Motor dysfunction in type 5 adenylyl cyclase-null mice J. Biol. Chem. 278 2003 16936 16940 (Pubitemid 36799567)
49. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease Exp. Neurol. 184 2003 285 294 (Pubitemid 37444038)
50. 2A receptor signaling Neurology 61 Suppl. 6 2003 S19 S23
51. C.L. Allan Schizophrenia: from genes to phenes to disease Curr. Psychiatry Rep. 10 2008 339 343
52. A.H. Wong, and H.H. Van Tol Schizophrenia: from phenomenology to neurobiology Neurosci. Biobehav. Rev. 27 2003 269 306 (Pubitemid 36681541)
53. T.F. McNeil Perinatal risk factors and schizophrenia: selective review and methodological concerns Epidemiol. Rev. 17 1995 107 112
54. S.L. Buka, and A.P. Fan Association of prenatal and perinatal complications with subsequent bipolar disorder and schizophrenia Schizophr. Res. 39 1999 113 119 (Pubitemid 29415682)
55. T.D. Cannon Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions Schizophr. Bull. 29 2003 653 669 (Pubitemid 38181948)
56. H.O. Kalkman Altered growth factor signalling pathways as the basis of aberrant stem cell maturation in schizophrenia Pharmacol. Ther. 121 2009 115 119
57. J.J. McGrath The neurodevelopmental hypothesis of schizophrenia: a review of recent developments Ann. Med. 35 2003 86 93 (Pubitemid 36638211)
58. N.E.M. Van Haren Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood Biol. Psychiatry 63 2008 106 113
59. A. Buonanno The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits Brain Res. Bull. 83 2010 122 131
60. M. Niwa Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits Neuron 65 2010 480 489
61. Y. Goto, and A.A. Grace The dopamine system and the pathophysiology of schizophrenia: a basic science perspective Int. Rev. Neurobiol. 78C 2007 41 68
62. E.J. Hess Dopamine receptor subtype imbalance in schizophrenia Life Sci. 40 1987 1487 1497 (Pubitemid 17040520)
63. J.L. Waddington The neurodevelopmental basis of schizophrenia: clinical clues from cerebro-craniofacial dysmorphogenesis, and the roots of a lifetime trajectory of disease Biol. Psychiatry 46 1999 31 39 (Pubitemid 29296816)
64. M. Laruelle Glutamate, dopamine and schizophrenia: from pathophysiology to treatment Ann. N.Y. Acad. Sci. 2003 138 158 (Pubitemid 38083052)
65. A. Abi-Dargham, and M. Laruelle Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies Eur. Psychiatry 20 2005 15 27 (Pubitemid 40092387)
66. C. Kellendonk Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning Neuron 49 2006 603 615 (Pubitemid 43221894)
67. A. Sidhu, and H.B. Niznik Coupling of dopamine receptor subtypes to multiple and diverse G proteins Int. J. Dev. Neurosci. 18 2000 669 677 (Pubitemid 30649689)
68. S. Nikolaus In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders Behav. Brain Res. 204 2009 32 66
69. K.W. Lee Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase Neuroscience 22 2002 7931 7940
70. K.S. Kim Adenylyl cyclase-5 activity in the nucleus accumbens regulates anxiety-related behavior J. Neurochem. 107 2008 105 115
71. R. Molteni Antipsycotic drug actions on gene modulation and signaling mechanisms Pharmacol. Ther. 124 2000 74 85
72. F. Agasse Response to histamine allows the functional identification of neuronal progenitors, neurons, astrocytes, and immature cells in subventricular zone cell cultures Rejuvenation Res. 11 2008 187 200 (Pubitemid 351271634)
73. R.G. Tremblay Differentiation of mouse Neuro2A cells into dopamine neurons J. Neurosci. Methods 186 2010 60 67
74. H.S. Yung Nerve growth factor-induced differentiation of PC12 cells is accompanied by elevated adenylyl cyclase activity Neurosignals 18 2010 32 42
75. M. Engelhardt Adult retinal pigment epithelium cells express neural progenitor properties and the neuronal precursor protein doublecortin Brain Res. 1040 2005 98 111 (Pubitemid 40459625)
76. C.W. Pouton, and J.M. Haynes Pharmaceutical applications of embryonic stem cells Adv. Drug Del. Rev. 57 2005 1918 1934 (Pubitemid 41682363)
77. S. Ding, and P.G. Schultz A role for chemistry in stem cell biology Nat. Biotechnol. 22 2004 833 840 (Pubitemid 38886601)
78. F. Kaya Ascorbic acid is a regulator of the intracellular cAMP concentration: old molecule, new functions? FEBS Lett. 582 2008 3614 3618
79. H.F. Wang, and F.C. Liu Regulation of multiple dopamine signal transduction molecules by retinoids in the developing striatum Neuroscience 134 2005 97 105
80. W.C. Putnam Identification of a Forskolin-like molecule in human renal cysts J. Am. Soc. Nephrol. 18 2007 934 943 (Pubitemid 46434510)
81. S. Pierre Capturing adenylyl cyclases as potential drug targets Nat. Rev. Drug Discov. 8 2009 321 335
82. T. Onda Type-specific regulation of adenylyl cyclase J. Biol. Chem. 278 2001 47785 47793
83. K. Iwatsubo Drug therapy aimed at adenylate cyclase to regulate cyclic nucleotide signaling Endocr. Metab. Immune Disord. Drug Targets 6 2006 239 247 (Pubitemid 44383207)
84. K. Iwatsubo Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy Expert Opin. Ther. Targets 7 2003 441 451 (Pubitemid 36722228)
85. Y. Toya Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase J. Mol. Cell. Cardiol. 30 1998 97 108 (Pubitemid 28069748)
86. C. Pinto Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs J. Pharmacol. Exp. Ther. 325 2008 27 36 (Pubitemid 351439155)
87. H. Wang Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain Sci. Transl. Med. 3 2011 65ra3
88. D. Levy Hydroxamate based inhibitors of adenylyl cyclase. Part 1. The effect of acyclic linkers on P-site binding Biorg. Med. Chem. Lett. 12 2002 3085 3088
89. D. Levy Hydroxamate based inhibitors of adenylyl cyclase. Part 2. The effect of cyclic linkers on P-site binding Biorg. Med. Chem. Lett. 12 2002 3089 3092
90. D.E. Levy Metal coordination-based inhibitors of adenylyl cyclase: novel potent P-site antagonists J. Med. Chem. 46 2003 2177 2186 (Pubitemid 36583496)
91. A. Gille, and R. Seifert 2′(3′)-O-(N-methylanthraniloyl)- substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors J. Biol. Chem. 278 2002 12672 12679 (Pubitemid 36800027)
92. A. Gille Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides J. Biol. Chem. 279 2003 19955 19969
93. G. Tosi Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123 J. Control. Release 122 2007 1 9 (Pubitemid 47284547)
94. A. Dalpiaz Brain uptake of an anti-ischemic agent by nasal administration of microparticles J. Pharm. Sci. 97 2008 4889 4903
95. K.B. Kurakhmaeva Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles J. Drug Target. 17 2009 564 574
96. T. Vierbuchen Direct conversion of functional neurons to fibroblasts by defined factors Nature 463 2010 1035 1041
97. J. Hanna Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs Proc. Natl. Acad. Sci. U.S.A. 107 2010 9222 9227